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Dedication 
 
To Mr. Schaberg, who made learning science fun, in the 6th grade and for a lifetime.  
“Hello boys and girls, let’s learn!” 
 ii 
Abstract 
Mate-pair sequencing (MPseq), using long-insert, paired-end genomic libraries, is a powerful 
next-generation sequencing-based approach for the detection of genomic structural variants. 
SVAtools is a set of algorithms to detect both chromosomal rearrangements and large (>10kb) 
copy number variants (CNVs) in genome-wide MPseq data. SVAtools can also predict gene 
disruptions, gene fusions, and characterize the genomic structure of complex rearrangements.  
 
To illustrate the power of SVAtools’ junction detection methods to provide comprehensive 
molecular karyotypes, MPseq data was compared against a set of samples previously 
characterized by traditional cytogenetic methods. Karyotype, fluorescence in situ hybridization 
(FISH) and chromosomal microarray (CMA), performed for 29 patients in a clinical laboratory 
setting, collectively revealed 285 breakpoints in 87 rearrangements. The junction detection 
methods of SVAtools detected 87% of these breakpoints compared to 48%, 42% and 57% for 
karyotype, FISH and CMA respectively. Breakpoint resolution was also reported to 1 kb or less 
and additional genomic rearrangement complexities not appreciable by standard cytogenetic 
techniques were revealed. For example, 63% of CNVs detected by CMA were shown by 
SVAtools’ junction detection to occur secondary to a rearrangement other than a simple deletion 
or tandem duplication. SVAtools with MPseq provides comprehensive and accurate whole-
genome junction detection with improved breakpoint resolution, compared to karyotype, FISH, 
and CMA combined. This approach to molecular karyotyping offers considerable diagnostic 
potential for the simultaneous detection of both novel and recurrent genomic rearrangements in 
hereditary and neoplastic disorders. 
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Chapter 1: Introduction and background 
 
Structural variants (SVs), including balanced and unbalanced chromosomal rearrangements and 
copy number variants (CNVs) are a significant contributor to both neoplastic and hereditary 
disorders. Germline SVs can produce an adaptive advantage, but most often have a negative 
consequence leading to aneuploidy, infertility or disease; cancer is often a result of somatic SVs 
(Feuk, Carson, and Scherer 2006; Stankiewicz and Lupski 2010; Weischenfeldt et al. 2013). 
Characterizing and understanding the mechanisms of SVs is dependent on the ability to 
accurately detect SVs (Weckselblatt and Rudd 2015; Chen et al. 2010; South 2011). 
 
SVs are routinely detected by standard cytogenetic methods: karyotype, fluorescence in situ 
hybridization (FISH) and genomic copy number microarrays, or chromosomal microarrays (CMA). 
Karyotyping by conventional, G-banded, giesma stain to identify banding patterns on 
chromosomes, provides a whole-genome analysis and is suitable for detecting large 
rearrangements. However, karyotyping requires dividing cells arrested in metaphase, which can 
be difficult to retrieve from some sample sources. Additionally, because metaphase 
chromosomes are highly condensed, karyotyping has variable and relatively low resolution, at 
best 3-10 Mb. FISH involves fluorescently labeled DNA probes which hybridize to a genomic 
region (~200 kb) of interest. The resulting fluorescent patterns on interphase or metaphase 
preparations reveal genomic regions of increased or decreased copy number and/or specific 
rearrangements. The utility of FISH is primarily limited by the a priori need to know which 
genomic region to interrogate and limited to the number of probes that can be multiplexed in a 
single analysis. CMA, through various methodologies, provides a whole-genome copy number 
scan by comparing the relative ratio of patient DNA to control. For most CMA assays in clinical 
use, CMA has the ability to detect regions of copy number change at a resolution of 
approximately 25-400 kb throughout the genome, down to <10 kb for targeted regions, depending 
on the number of probes on the array (Kearney et al. 2011). The primary limitation of CMA is the 
inability to detect balanced rearrangements or clarify the structural configuration of detected 
CNVs, e.g., a copy number gain may be the result of a direct tandem duplication, inverted 
duplication, or an insertional translocation elsewhere, and making this distinction may have 
significant interpretive consequence (Newman et al. 2015).  
 
Whole-genome, read-pair next generation sequencing (NGS) acquires the DNA sequence of an 
organism. DNA is fragmented, sequenced from both ends, and mapped to a reference genome. 
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Mate-pair sequencing (MPseq) represents a variation of standard paired-end sequencing utilizing 
large genomic inserts, 2-5 kb, which are circularized and fragmented to the standard paired-end 
protocol length, 200-500 bps, Figure 1.1. Both MPseq and standard paired-end are whole 
genome, can provide base pair resolution (given adequate sequencing depth) and are capable of 
detecting balanced and unbalanced rearrangements (Korbel et al. 2007; Alkan, Coe, and Eichler 
2011). MPseq however, offers additional advantages over standard paired-end sequencing. The 
larger fragments improve mapping accuracy in repeat areas (Medvedev, Stanciu, and Brudno 
2009) and allow for significantly more efficient capture of junctions associated with SVs, thus 
providing a less expensive technique for SV detection. 
 
 
Figure 1.1: MPseq fragment circularization 
DNA is prepared for MPseq using the Nextera mate-pair library protocol and sequenced on 
the Illumina HiSeq platform. To make mate-pair libraries, DNA is fragmented to 2-5kb 
pieces and the terminal ends are labeled with biotin (B). These fragments are circularized 
and re-fragmented to smaller ~500 bps pieces. A capture step selects the biotin labeled 
fragments and these ends are then sequenced. The red and blue segments represent the 
101 bps reads that are sequenced, and the mapped strand orientation of that read, red for 
reverse strand, blue for forward strand. This long insert size gives MPseq the ability to 
detect structural variants with less sequencing (cheaper) than traditional whole genome 
sequencing with paired-end sequencing. 
 
The SV detection pipeline established by Biomarker Discovery (BMD) at Mayo Clinic 
(http://mayoresearch.mayo.edu/center-for-individualized-medicine/biomarker-discovery-
program.asp) includes guidelines for DNA preparation, library preparation, multiplex sequencing 
and sequencing analysis with BIMA and SVAtools. The BMD-SV pipeline has demonstrated 
considerable utility since its first implementation in 2011 (Feldman et al. 2011; Vasmatzis et al. 
2012; Murphy et al. 2012; Murphy et al. 2014; Boddicker et al. 2016; Harris et al. 2016 ; Catic et 
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al. 2017). The BMD-SV pipeline does not require matched tumor/normal samples and is suitable 
for calling SVs from fresh or frozen DNA collected from solid tumors and soft tissue cancers, and 
blood or bone marrow sampled from constitutional disorders or hematological malignancies.  
 
This thesis introduces SVAtools and describes the junction detection algorithm (SVAtoolsJD) for 
analyzing MPseq data. The sensitivity and junction detection performance of SVAtoolsJD is 
compared to traditional cytogenetic techniques. Also demonstrated are the additional advantages 
of MPseq and SVAtoolsJD over traditional cytogenetic techniques, including ability to: a) resolve 
the genomic architecture of the SVs detected; b) predict gene fusions and gene truncations; and 
c) obtain high resolution (~200 bp) of breakpoints. The CNV detection of SVAtools (Smadbeck et 
al.) would improve the overall sensitivity of MPseq, but was out of scope for this thesis 
Chapter 2: Methods 
2A: Terminology and junction signatures 
Structural variants include rearrangements and CNVs. Rearrangements, such as inversions, 
deletions, tandem duplications, and translocations, involve a number of breaks and reunions. To 
facilitate discussion, we use the following nomenclature: 
• Breakpoint: location left or right of a break in the genome 
• Junction: the reunion of a break, two distal breakpoints are now adjacent 
• Rearrangement: chromosome structure abnormality due to one or more junctions, such 
as a deletion, inversion, translocation, etc. 
• Bridged Coverage: average number of fragments (read-pairs) spanning a position in the 
diploid genome 
The breakpoints and junctions of non-complex rearrangements are illustrated in Figure 2A.1. For 
each rearrangement, a chromosome schematic is shown adjacent to an example junction plot 
produced by SVAtools. 
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Figure 2A.1: Junction signatures for non-complex rearrangements 
Rearrangements occur due to one or more breaks in the genome. Junctions are the 
reunion of the breaks. Each junction will have two breakpoints (stars), one on each side of 
the break and reunion. Junction plots have a distinct pattern indicative the rearrangement 
type. Non-complex rearrangements are depicted by the chromosome schematic (left) and 
junction plot (right). The orientation of the junction in the chromosome schematic (black 
box), corresponds directly to the orientation of the junction in the junction plot. A) 
Rearrangements with four breakpoints and two junctions include: inversions and 
reciprocal translocations. B) Rearrangements with two breakpoints and one junction 
include: derivative translocations, deletions and duplications. 
 
By the break, reunion, and junction convention defined here, the terminal edge of a terminal CNV 
was not included in the breakpoint count and the non-terminal edge was included only if the CNV 
occurred with a junction. For example, the centromeric breakpoint of a whole arm CNV due to a 
translocation was included, while whole chromosome CNVs, such as monosomy and trisomy, 
were excluded. While not discussed here, terminal CNVs are detectable by SVAtools’ CNV 
detection methods; full details will be provided in the upcoming paper by Smadbeck et al.  
 
Coverage estimations provide thresholds to confidently call variants. Base coverage (often 
referred to as depth of coverage, read depth, or coverage) is dependent on the count and length 
of reads sequenced, and therefore, on total sequenced nucleotides. SVAtools uses a count of the 
number of fragments spanning a given position, “bridged coverage” to establish confidence for 
each SV detected. Bridged coverage will depend on the number of fragments and the length the 
fragments (read lengths plus insert length). Figure 2A.2 illustrates a pile-up of 16 fragments 
mapped to a reference. For the given position X, the bridged coverage is 14x, while the base 
coverage is only 2x. Because the insert size is large, often 2-5kb, the bridged coverage will be 
much higher than the base coverage. For example, given 100,000,000 fragments with 2 reads of 
length 100bp and assuming uniform mapping to GRCh38 (3.2x109 bp), base coverage is 6.25x. If 
the insert size is 2800, for a total fragment length of 3000, the bridged coverage is 93.75x, a 15-
fold increase for the same amount of sequencing.  
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Figure 2A.2 Schematic pile up of 16 mate-pair fragments mapped to a reference. 
The red and blue segments of each fragment represent the two mapped reads, black is the 
unsequenced and inferred insert region. The number of fragments spanning position X 
determines the bridged coverage of that position. To determine the resolution of the 
breakpoint position based on bridged coverage consider: 1) the breakpoint will be in-
between two discordant reads from the same fragment, thus the breakpoint must be no 
further than the fragment length; 2) in a worst case scenario the breakpoint is exactly in 
the middle of a spanning fragment, therefore the breakpoint accuracy is at least half the 
fragment length; 3) odds are the breakpoint will be close to one read from one fragment 
and close to another read from a different fragment, providing accuracy within a couple 
hundred bps; 4) SVAtoolsJD includes split reads in the junction detection; when available 
these split reads will contain the actual breakpoint.  
 
2B: Cytogenetic Analysis  
A test set of representative breakpoints were identified from the results of three cytogenetic 
methods. The sample selection included patients referred to the Mayo Clinic Cytogenetics 
Laboratory for karyotype and/ or FISH testing of hematologic neoplasms such as acute myeloid 
leukemia, acute lymphocytic leukemia and chronic lymphocytic leukemia. All samples were 
processed using standard clinical protocols for the three methods: karyotype, FISH and CMA 
(Affymetrix CytoScan HD array, analyzed using ChAS and manually reviewed). Two samples 
were excluded because they did not have at least one rearrangement from at least one of the 
three methods. One sample with an exceedingly complex genomic structure, 42-45,XX,psu 
dic(9;12)(p13;p11.2)[4],add(11)(p11.2),-16,-17[4],-19[3], +der(?)t(?;16)(?;q11.1),+1-
3mar[cp5]//46,XY[15] was also excluded as it was not feasible to delineate specific 
rearrangements for an organized point by point technical comparison in the way chosen for this 
report. All clinically reported findings for each method were included in this report (Table 1). The 
final sample selection of 29 cases included a range of typical and straightforward cases to cases 
with challenging and complex clonal rearrangements. 
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Table 2B: Clinically reported results for karyotype, FISH, and CMA for 29 representative samples of hematologic neoplasm. 
Sample  Reason for Referral Karyotype Abnormal FISH CMA (converted to GRCh38) 
EV88044 AML 
46,XX,t(15;17)(q22;q21)[17]/46,XX,der(
15)t(15;17)(q22;q21),ider(17)(q10)t(15;
17)(q22;q21)[3] 
(PMLx3),(RARAx3),(PML con 
RARAx2)[398/500]/ 
(PMLx4),(RARAx4),(PML con 
RARAx3)[79/500] 
15q24.2q26.3(75655926_101991189)x3[0.15] 
17p13.3p11.2(150732_19941963)x1[0.15]  
17p11.2q12(22266396_39610173)x3[0.15] 
EV88048 Myelofibrosis 46,XX[20] 
 
2q31.3q32.1(181249078_183436911)x3 
EV88059 CLL 46,XY,t(5;6)(q13;q23)[10]/47,XY,+12[2]/46,XY[8] 
(D13S319x1),13q34(LAMP1x2)[112/
200] 
6q14.3q22.1(85398516_116240537)x1[0.4],  
6q25.2q25.3(154631808_157214436)x1[0.4], 
13q14.2q14.2(47898938_49957631)x1[0.5], 
13q14.2q14.3(50108920_50922184)x1[0.5] 
EV88060 CLL 46,Y,inv(X)(p?21q?21)?c[13] (D13S319x0),13q34(LAMP1x2)[158/200] 
13q14.2q14.3(49925862_50516172)x1[1.7], 
13q14.3q14.3(50519349_51037765)x1[0.5] 
EV88061 CLL 46,XY,der(2)t(2;7)(q31;q32),der(7)add(7)(p13)t(2;7)[2]/46,XY[15] 
(D13S319x1),13q34(LAMP1x2)[107/
200] 
2p23.1p22.3(31802162_32393289)x1[0.3] 
2p13.1p13.1(73555116_74697219)x1[0.4] 
7p21.3p21.3(7398184_8546126)x1[0.4] 
13q14.11q14.11(40904307_43361934)x1[0.25] 
13q14.11q14.2(43368704_48382057)x1[0.5] 
13q14.2q14.3(48386316_51084046)x1 
13q14.3q21.1(51085062_56092156)x1[0.5] 
13q21.1q21.32(56104664_66805369)x1[0.25] 
EV88063 ALL 46,XX,t(4;11)(q21;q23)[10]/46,idem,i(7)(q10)[10] 
(AFF1x3),(KMT2Ax3),(AFF1con 
KMT2A)[396/500] 
(7p)x1[0.3] 
(7q)x3[0.3] 
9p21.3p21.3(21178271_22202761)x1[1.5] 
EV88064 acute leukemia 46,XX[8]  
6p12.1p12.1(53161778_53731152)x3[1.25] 
6p11.2p11.2(57965290_58306189)x3[0.75] 
EV88065 CML 46,XY,t(9;22;15)(q34;q11.2;q15)[20] (ABL1x3),(BCRx3),(ABL1 con BCRx1)[464/500] 18p11.32p11.32(1194375_1640812)x1 
EV88070 MPD with 
eosinophilia 46,XY[20] 
(FIP1L1x2,CHIC2x1,PDGFRAx2)[13
3/200] 4q12q12(53427547_54274695)x1[0.6] 
EV88073 
AML with 
monocytic 
different-
iation 
46,XX,t(11;19)(q23;p13.1)[20] (KMT2Ax3),(ELLx3),(KMT2A con ELLx2)[491/500] 
12q24.23q24.23(118516990_118588890)x1[0.4] 
16q23.1q23.1(78229384_78352174)x1[0.8] 
17q25.1q25.1(73839502_74684979)x3[1.2] 
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Sample  Reason for Referral Karyotype Abnormal FISH CMA (converted to GRCh38) 
EV88074 CML 46,XY,t(11;13)(q23;q14)[17]/46,XY[3] (D13S319x1,LAMP1x2)[126/200] 
11q23.3q23.3(119067603_121113378)x1[0.7] 
13q14.2q14.3(47767418_51606370)x1[0.7] 
18q21.2q21.31(55080639_56205472)x1[0.7] 
22q11.22q13.2(23101973_43489488)x1[0.1] 
EV88076 
new 
aggressive 
lymphoma 
46,XY[5] (MYCx3),(IGHx2),(MYC con IGHx1)[219/500] 1q21.1q25.3(146149859_184080669)x3[0.3] 
EV88078 leukocytosis 46,XX,t(9;22)(q34;q11.2)[20] (ABL1x3),(BCRx3),(ABL1 con BCRx2)[486/500] arr(1-22,X)x2 
EV88079 
post 
transplant 
lymphopro-
liferative 
disorder 
46,XY,t(9;11)(p22;q23)[20] (MLLT3x3),(KMT2Ax3),(MLLT3 con KMT2Ax2)[465/500] arr(1-22)x2,(X,Y)x1 
EV88081 non-hodgkin lymphoma 46,XX[20] 
(AFF1x3),(KMT2Ax3),(AFF1 con 
KMT2Ax1)[167/500] 
1p36.33p36.23(1959099_7949703)x1[0.4] 
1p13.1p13.1(115806740_116739470)x1[0.5] 
4p15.1p15.1(30992588_31966163)x1[0.4] 
6q14.1q22.1(80892556_114303640)x1[0.5] 
9p24.3p21.3(203861_21572243)x1[0.5] 
9p21.3p21.3(21579259_22075597)x1[0.8] 
9p21.3p21.2(22081850_26050211)x1[0.5] 
12q13.13q13.13(52294886_52388067)x3 
15q22.2q22.2(61453278_61592715)x3 
17p13.3p13.3(150732_2931676)x1[0.5] 
17p13.3p13.3(2936307_3391011)x1[0.8] 
17p13.2p11.2(3397639_21542019)x1[0.5] 
88083 
anemia, 
thrombo-
cytopenia, 
AML 
 
46,XX,t(6;9)(p23;q34)[8]/46,XX[1] (DEKx3),(NUP214x3),(DEK con NUP214x2)[480/500] 
6p22.3p22.3(18119418_18226579)x1[0.75] 
9q34.13q34.13(131132438_131153811)x1[0.5] 
88085 leukocytosis 46,Y,t(X;10;9;22)(q11;p13;q34;q11.2)[19]/47,idem,+8[1] 
(ABL1x3),(BCRx3),(ABL1 con 
BCRx1)[405/500] arr(1-22)x2,(X,Y)x1 
EV88086 lymphoma 46,XY,t(2;11)(p25;q23)[1]/46,idem,-Y,+8[2]/46,XY[2] 
(CDKN2Ax1,D9Z1x2)[98/200]/(3'IGH
x2,dim5'IGHx2)[104/200],  
ish t(2;11)(KMT2A+;KMT2A-)[2] 
9p21.3p21.3(21817336_21968663)x1[0.5] 
9p21.3p21.3(21976746_22005383)x1[0.75] 
9p21.3p21.3(22009308_22104160)x1[0.5] 
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Sample  Reason for Referral Karyotype Abnormal FISH CMA (converted to GRCh38) 
11q22.1q22.1(99772315_100264159)x3[0.5] 
11q22.3q23.3(103229656_115453069)x1[0.5] 
(8)x3[0.2] 
(Y)x0[0.5] 
EV88088 AML 47,XY,+8,t(9;11)(p22;q23)[20] (MLLT3x3),(KMT2Ax3),(MLLT3 con KMT2Ax2)[488/500] 
9p22.1p22.1(19072482_19320487)x3 
(8)x3 
(Y)x2[0.5] 
EV88089 granulocytic 
sarcoma 
46,X,-
Y,t(8;21)(q22;q22),+9,del(9)(q13q32)x2
[5]/46,XY[15] 
(RUNX1T1x3),(RUNX1x3),(RUNX1T
1 con 
RUNX1x2)[31/500]/(ABL1x3,BCRx2)[
18/500] 
9q21.11q31.2(68351345_107847887)x1[0.1] 
(Y)x0[0.2] 
EV88090 CMPD 46,XX,t(9;22)(q34;q11.2)[19]/46,XX[1] (ABL1x3),(BCRx3),(ABL1 con BCRx2)[469/500] 
9q34.11q34.12(130419555_130717717)x1[0.75] 
22q11.23q11.23(23293899_23414891)x1[0.75] 
EV88091 
Acute 
leukemia, 
bilineage, T-
cell and 
myeloid 
46,XY,del(9)(q13q22)[9]/46,XY[11] (TLX3x3),(BCL11Bx2),(TLX3 con BCL11Bx1)[424/500] 
9p21.3p21.3(21828043_21996864)x1[0.75] 
9q21.13q31.2(71857107_107192688)x1[0.5] 
EV88094 AML 
48,XY,t(1;3)(q32;p25),add(6)(p21.3),+1
3,inv(16)(p13.1q22), 
der(18)t(1;18)(q21;q21),+20[20] 
(MYH11x3),(CBFBx3),(MYH11 con 
CBFBx2)[214/500]/ 
(D13S319,LAMP1)x3[93/200]/(D20S
108,20qter)x3[91/200] 
1q24.3q44(171641445_249000000)x3[0.3] 
3p25.2p25.2(12582218_12675079)x1 
7q34q34(142251693_143399068)x1[0.5] 
11q22.1q25(100524067_135068576)x3[0.3] 
(13)x3[0.3] 
18q22.2q23(69603144_80256240)x1[0.3] 
(20)x3[0.3] 
EV88096 acute leukemia 
46,XY,inv(2)(p11.2q13)[5]/46,XY[15] 
  
2q14.2q21.1(120599518_130388693)x1[0.3] 
8q24.13q24.21(125355953_129686186)x1[0.3] 
EV88099 T-ALL 48,X,t(X;10)(q24;p13),+1,+4[6]/46,XX[14] 
(STIL,TAL1)x3[125/200]/(MLLT10x3)[
355/500] 
(1)x3[0.6] 
(4)x3[0.6] 
6q23.3q23.3(135091879_135409387)x3 
16q22.1q22.1(66990865_67774694)x1[0.6] 
 
EV88100 
 
 
acute 
leukemia, 
MDS 
46,XX,inv(3)(q21q26.2),del(5)(q13q33),
add(17)(p13)[20] 
(RPN1x3),(EVI1x3),(RPN1 con 
EVI1x2)[454/500]/(D5S630x2,EGR1x1) 
[198/200]/(MLLx3)[185/200] 
5q14.2q33.2(82326551_153894589)x1[0.9] 
11q23.1q25(112186582_135068576)x3[0.9] 
17p13.3p13.1(150732_8158478)x1[0.8] 
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Sample  Reason for Referral Karyotype Abnormal FISH CMA (converted to GRCh38) 
EV88101 
anemia, 
fever, bone 
pain 
46,XX,del(11)(q21q23),t(11;15)(q11;q1
1.2),add(19)(q13.1)[2]/ 
47,idem,t(5;9)(q11.2;p22),+21[1]/46,XX
[17] 
(CDKN2Ax0,D9Z1x2)[20/200]/(ETV6
x2),(RUNX1x3),(ETV6 con 
RUNX1x2)[387/500]/(ETV6x2),(RUN
X1x4),(ETV6 con RUNX1x2)[30/500] 
2p11.2p11.2(88600364_88829551)x1 
9p22.1p21.3(19589909_21800760)x1[0.3] 
9p21.3p21.3(21807994_22492877)x0[0.5] 
9p21.3p21.3(23971816_25466630)x1[0.2] 
12p13.2p13.1(11618063_13133213)x1 
17q11.1q11.2(27344679_30233516)x1[0.1] 
17q11.2q12(30233516_37700251)x1[0.6] 
17q12q23.2(37710931_62716038)x3[0.5] 
17q23.2q24.1(62718712_66002488)x1[0.6] 
(21)x3[0.2] 
EV88102 B-ALL 46,XX[20] (CDKN2Ax1,D9Z1x2)[40/200] 
2p14p11.2(64635266_88825975)x1[0.8] 
6q14.1q22.1(78827961_115307126)x1 
6q24.2q25.1(143704644_149826658)x1 
9p22.1p21.3(19625174_21767405)x1[0.2] 
9p21.3p21.3(21772930_22215463)x1[0.4] 
12p13.2p13.2(11639155_11747039)x1 
12q21.33q21.33(91813602_92157567)x1 
16p13.3p13.3(3777822_3867646)x3 
17p13.3p13.1(159683_8094096)x1[0.7] 
(X)x1[0.7] 
EV88103 lymphoma 
45,X,-X, dup(1)(q11q32), 
t(3;7)(q27;q22)[15],t(8;14;18)(q24.1;q3
2;q21.3),der(14)t(8;14;18)[2][cp20] 
(MYCx3),(IGHx4),(MYC con 
IGHx2)[445/500]/(IGHx4),(BCL2x3),(I
GH con BCL2x2)[424/500] 
1q21.1q24.2(144009402_168910115)x3[0.75] 
1q24.2q24.2(168915824_169888200)x1[0.25] 
1q24.2q41(169892108_222802457)x3[0.75] 
2p16.1p15(59929961_63403720)x3[0.9] 
9p21.3p21.3(21604467_22258903)x1[1.6] 
12q24.31q24.31(121574607_122813944)x1[0.75] 
16q23.1q23.1(78701427_78967038)x1[0.75] 
18p11.31p11.23(5594352_7718922)x1[0.2] 
22q13.1q13.2(39447775_40832804)x1[0.8] 
(X)x1[0.8] 
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2C: MPseq analysis, SVAtools and the junction detection algorithms  
2C-1: BMD-SV Pipeline Overview 
DNA from the 29 representative clinical cytogenetic samples was tested by the BMD-SV pipeline. 
Bulk-extracted DNA libraries for each sample were prepared following the Illumina Nextera Mate-
Pair Library Prep protocol (Illumina, San Diego, CA, USA). Sequencing was performed two 
samples per lane on the Illumina HiSeq2000, with 101-basepair (bp) read length. The sequencing 
data was mapped to GRCh38 by BIMA (Drucker et al. 2014). SV detection was performed by 
SVAtools. Figure 2C.1 provides sequencing statistics for each of the 29 samples. Average 
bridged coverage for the 29 samples was 60x. Figure 2C.2 provides a histogram of fragment 
lengths for a typical MPseq library. The algorithmic workflow for the BMD-SV pipeline is shown in 
Figure 2C.3. 
 
Figure 2C.1: MPseq quality statistics for the 29 samples.  
Average bridged coverage was 60x. The high bridged coverage is a result of the large 
number of fragments (average ~80 million/ sample), low % replication, low % unmapped 
fragments, and the large fragment size (mode = ~2000 bp, mean =~3000bp).  
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Figure 2C.2: Fragment length histogram of a typical MPseq library 
Fragment length versus frequency. The red line peaking at 2352 bps indicates the 
frequency of reverse-forward mapping fragments, typically mate-pair fragments, given the 
reversal of orientation of the reads due to the circularized intermediate in the library 
preparation. The blue line indicates the frequency of forward-reverse mapping fragments, 
typically paired-end fragments. Paired-end fragments exist in our MPseq library 
preparations at a typical ratio of 3:1. 
 
2C-2: Mapping - BIMA to Map MPseq libraries 
BIMA was previously published by BMD (Drucker et al. 2014). BIMA converts the DNA alphabet 
to binary (the computer alphabet) using three encodings: A/G, C/G, and A/C, where the two listed 
bases are converted to 1 and the remaining two bases are converted to 0. BIMA converts each 
sequential 32 bases to a 32 bit binary number, which is then used as an index to a series of hash 
tables and look up tables. This fast lookup algorithm, combined with binary operations, enables 
BIMA to map 100 million mate-pair fragments to the 3.2 billion base reference genome faster than 
other algorithms (Drucker et al. 2014). The conversion of the reference genome and the reads 
from each fragment allows each base to be uniquely identified in binary. This conversion also 
allows for single nucleotide variants without loss of information.  
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BIMA maps both reads from a fragment concurrently to facilitate more accurate mapping, such as 
when one read maps to multiple positions, the other read can serve as an anchor to determine 
the correct position of the former. BIMA scores each mapping option and reports the position with 
the best score. When the same best score occurs for multiple mapping options, BIMA defaults to 
the position that occurs first by numerical order of the chromosome and then chromosome 
position. When BIMA detects a split read, two alignments will be reported. If BIMA cannot map a 
read, or the read maps to too many places, BIMA will map the read to chromosome 0, position 0. 
These fragments remain available for in-depth downstream processing. Since over 5% of the 
GRCh38 reference genome is not sequenced, at least 5% of all fragments should not map. On 
average, less than 5% of all fragments cannot be mapped by BIMA, thus there is some over-
mapping by BIMA.  
 
BIMA reports for each read the chromosome (chr), position (pos), and mapping metrics to 
facilitate junction detection by SVAtoolsJD. BIMA nomenclature designates readA and readB of a 
read-pair in numerical order of the mapped position. Thus, chrA/posA for readA will always be the 
lower numbered chromosome and the lower position compared to chrB/posB for readB. BIMA 
can map to any reference genome of any length with any number of chromosomes. In this 
implementation, BIMA maps to GRCh38, which includes chromosomes X, Y, 1-22, plus the 
unlocalized, unplaced, and alternate sequences. For other applications, such as for detecting 
virus integration into the human genome (Gao et al. 2014), BIMA mapped to a reference genome 
created by concatenating GRCh38 with genomes from over 5000 viruses.  
 
BIMA supports two file options for reporting mapping results: 1) .sva for importing into 
SVAtoolsJD and 2) SAM. A .sva file is generated for each chromosome in the reference genome. 
This sorting facilitates faster downstream processing than SAM files because: 1) SVAtoolsJD can 
parallel process data for each chromosome; and 2) related fragments are stored in smaller files 
and closer to each other, crucial for on demand visualization. 
 
BIMA’s flexibility allows for any insert size, mapping both paired-end and mate-pair fragments, 
important as both are present in a mate-pair library. Furthermore, BIMA is specially tuned to 
handle split reads which occur when the read crosses the breakpoint or crosses through the 
biotin junction of mate-pair libraries (up to 20% of mate-pair fragments).  
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Figure 2C.3: BMD-SV algorithmic pipeline.  
Each step can be executed independently, as a group, or sequentially from start to finish. 
BIMA, written in C, takes fastq files as input and maps to the requested reference genome, 
i.e. GRCh38. SVAtoolsJD, written and packaged in R, contains the remaining steps of the 
pipeline. The inputs are the .sva files produced by BIMA and the final outputs are .csvs, 
.pdfs, and .json files for listing and visualizing the reported SVs.  
 
2C-3: SV detection – SVAtools to process BIMA output 
SVAtools is a library written and packaged in the R software environment. SVAtools is capable of 
detecting SVs from NGS including: MPseq, traditional paired-end, custom capture (Jang et al. 
2016) and amplicon sequencing. The SVAtools library operates in a series of steps (Figure 2C.3) 
that can be called individually, as a group, or in automatic succession. This flexibility allows “one-
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button” operation of the entire pipeline, and quick feedback when adjusting configuration 
parameters to fine tune SV detection sensitivity or specificity.  
 
The first algorithmic step, svaCleanAndCluster, operates in parallel on each of the 30 .sva files 
created by BIMA for GRCh38. Replicate fragments (also commonly called duplicates or non-
unique read-pairs) are identified and excluded from any further analysis. The remaining 
fragments are sorted and indexed for faster downstream operations. For memory conservation 
the original, but now redundant, .sva files can be deleted. SVAtools provides methods for 
recreating the .sva files if needed.  
 
To detect SVs, SVAtools combines three algorithmic approaches: read-pair, split-read, read 
depth/count (Tattini, D'Aurizio, and Magi 2015). SVAtoolsJD detects junctions by clustering the 
discordant read-pair and split-read fragments. Two or more discordant fragments supporting the 
same SV are identified as a “cluster” by the pipeline. Discordant fragments are those whose 
reads (readA and readB) map further apart than expected. SVAtools does not have an orientation 
requirement for distinguishing discordant from concordant fragments. Discordant fragments from 
both primary and split read mapping are clustered via a rapid custom clustering algorithm. The 
readA and readB positions are reduced from a 2-diminsional (1 position for each read in the 
fragment) to a 1-dimensional (1 position per fragment) array. Groups of fragments falling within a 
specified radius of each other along this 1-dimensional array are identified and clustered together. 
Details of each cluster, primarily fragment metrics such as total counts and size distributions, are 
concatenated and analyzed in the second step of SVAtools, combineFiles. Bridged coverage and 
base coverage calculations are also calculated, visualized, and stored.  
 
The next step, clusterCheck has two main purposes. The first is to determine the breakpoints for 
each junction. The second is to remove false positive clusters by masking and filtering. The 
breakpoint resolution of MPseq is dependent on the bridged-coverage, and therefore dependent 
on fragment length and number of fragments. Typically the breakpoint resolution is guaranteed 
within half the fragment length. A histogram of the fragment lengths from a typical MP library is 
shown in Figure 2C.2. In this example, the peak (mode) fragment length is 2352bp. Therefore, 
the breakpoints reported for this sample are accurate within 1176 bps (2352 / 2 bps). But often 
the breakpoint reported by SVAtoolsJD is within a couple hundred bps of the true breakpoint. 
Furthermore, SVAtoolsJD can find the exact breakpoints if split reads are present. Figure 2A.2 
demonstrates the resolution of the breakpoint position based on bridged coverage.  
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Masking and filtering reduces the false positive clusters to generate a reliable and meaningful list 
of junctions. Masking eliminates clusters detected in ‘normal’ samples free of cancer or 
constitutional diseases. Clusters may be detected in normal samples for several reasons. Normal 
sample clusters reveal: 1) likely benign variation present in the normal population but not in the 
reference genome; 2) artifacts incurred during the library prep; and 3) algorithmic artifacts, such 
as mapping errors due to errors or gaps in the reference genome, or repeat/homologous regions 
in the reference genome. These clusters are present in most samples sequenced by mate-pair 
and are therefore not diagnostically useful. The BMD-SV pipeline mask used in this study 
included clusters from 49 normal samples processed by the BMD-SV pipeline. 
 
Filters remove poorly qualified clusters based on cluster quality metrics and provides a 
mechanism to adjust the sensitivity and specificity for junction detection. Strict thresholds will 
exclude many false positives, but perhaps remove true positives. Lenient thresholds will likewise 
allow many false positives. The primary filters include: minimum number of fragments in a cluster, 
minimum and maximum cluster span (distance between the outermost reads in a cluster), 
number of mismatches within reads in a cluster, homology score (sequence similarity) of reads in 
a cluster, size of intra-chromosomal rearrangements, and ratio of reads mapping to the positive 
vs negative strand. Default settings to maximize sensitivity and specificity have been determined 
via sequencing and mapping over 2000 mate-pair samples from over 30 different diseases. 
Typical filter settings were applied to the 29 samples in this analysis. To eliminate chimeras 
formed during the MPseq library preparation, all clusters must have at least 3 fragments. Clusters 
spanning more than 20,000 bps or less than 250 bps were also discarded. All clusters must have 
at least one read with less than 3 mismatches, and an average homology score of 1.65 or less. 
The strict homology score allows for some fragments within the cluster to map to multiple 
positions, but ensures the cluster as a whole was uniquely mapped. Clusters with high homology 
can be rescued based on other criteria in later steps. 
 
The impact of masking versus filtering clusters for each sample is shown in Figure 2C.4. On 
average 32,800 clusters are detected for a sample, but only 14 are reported as junctions. 
SVAtoolsJD also provides methods to search for junctions manually. These methods help rule out 
false negative junctions, such as junctions that fail a filter or junctions with only 1 or 2 supporting 
fragments. These methods operate like FISH testing; the investigator must know which two 
genomic regions to interrogate and enables searching with much higher specificity than the 
standard pipeline. 
 18 
 
Figure 2C.4 Impact of masking vs filtering clusters on each of the 29 samples.  
On average, each sample will produce nearly 33,300 clusters of 2 or more discordant 
fragments. Fragments with both reads mapping to just chromosomes 1-22, X, and Y 
account for 80% of the clusters, the other 20% have at least one read mapping to an 
unlocalized, unplaced, or alternate genomic sequence. Only 46% of the clusters have at 
least 3 fragments or more. Clusters with just 2 fragments are primarily due to false 
ligations (chimeras), formed during the MPseq library prep. Masking eliminates 81% of all 
clusters, and filtering removes 98% of all clusters. In practice, filtering primarily removes 
clusters with low fragment counts, while masking removes clusters with high fragment 
counts but are thought to represent artifacts from the pipeline or common population 
variants. On average, out of 32,841 clusters, 14 are reported by SVAtoolsJD as putative 
junctions. 
 
The CNVdetect step assesses CNV using a read depth approach and the detected junctions to 
increase CNV sensitivity. The read depth approach uses the read count of concordant fragments, 
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~95% of all fragments in MPseq libraries, and assumes that after normalization they uniformly 
cover the reference genome sequence without bias. Regions that are found to have artificially 
high or low read depth are excluded. These regions are identified from the same 49 normal 
samples mentioned previously and are largely due to mapping artifacts. Normalization is 
performed by the normal sample with the highest copy number correlation to the patient sample. 
After normalization, a sliding window step detection algorithm is repeated for a range of window 
sizes from 100 kb – 1Mb to detect edges between regions with significant copy number 
difference. Breakpoints that are part of junctions found using the junction detection algorithms in 
SVAtools are added to the edge detection in order to supplement the statistically determined 
edges and improve sensitivity and resolution. The detected edges are used to segment the 
genomic data. Each segmented region is tested to determine which deviate significantly from the 
expected read depth and those with higher or lower read depth than expected are considered 
gains or losses, respectively. The algorithms can account for heterogeneous samples with 
numerous cell clones and are sensitive enough to easily detect CNVs when the cell population 
includes as little as 20% tumor. When less than 5% tumor, additional techniques are applied. 
Each CNV call is reported with a Normalized Read Depth score (NRD) to quantify the copy 
number level. Full details and analysis regarding CNV detection are provided in the forthcoming 
paper Smadbeck et al. 
 
The next step in SVAtoolsJD, clusterDoubleCheck, has two purposes: 1) review filtered clusters to 
unfilter those passing a second set of criteria; and 2) annotate and output the junctions to 
downloadable tables and graphics. Filtered clusters that are reviewed include clusters at non-
terminal CNV edges. Such clusters passing a relaxed set of filters can be confidently rescued 
because we expect a junction at all non-terminal edges of CNVs.  
 
2C-4: SV visualization – SVAtools to draw junction, region and genome plots 
The remaining steps create output for analysis and distribution among team members, provided 
in several forms: .csv data tables and .pdfs to visualize the SVs. Tables list the breakpoints for 
each detected junction and the CNV start and stop locations. Genome plots provide a whole-
genome snapshot of all detected junctions and CNVs. Figure 2C.5 provides two examples, a 
relatively stable and an unstable genome. Junction (Figure 2C.6A) and region plots (Figure 
2C.2B) show gene level detail of each reported junction. The final step, svaReport, assembles the 
pipeline information and results into a single pdf for quick and portable review. The pipeline 
information includes essential sample metadata and quality control statistics. 
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Figure 2C.5: Genome Plots 
In a genome plot, all chromosomes are displayed and arranged in a U-shaped 
configuration for efficient use of space. Each magenta line represents a junction reported 
by SVAtoolsJD. The endpoints of the line indicate the position of the two reported 
breakpoints, breakpoint A and B. The thickness of the line is proportional to the number of 
supporting fragments. Copy number is displayed by dot color and height above the 
idiogram for each chromosome. Neutral copy number is shown in gray, red for loss, and 
blue for gain. Areas with no dots, (centromeres and heterochromatin regions) remain 
unavailable in the GRCh38 reference genome and therefore fragments do not map to these 
areas. A) Genome plot with three detected junctions: a balanced inversion, a deletion CNV, 
and an unbalanced translocation. B) Genome plot of an unstable genome with numerous 
SVs involving over 30 junctions and many CNVs including whole arm and whole 
chromosome aneuploidy. 
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Figure 2C.6: Junction and region plot illustrating a 200kb deletion on chromosome 9.  
A) Junction plots are a vertically stacked two panel graph, one panel for each breakpoint, 
breakpoint A illustrated above breakpoint B. A genomic region, 30kb in this example, 
centered on the reported breakpoint is shown along the x-axis. Corresponding idiograms 
indicate the chromosomal position of the region by a red bar. The lines show the 
fragments that span the junction and support the rearrangement. The position of each 
read of a supporting fragment is located by a dot and color coded by strand, red for reads 
mapping to the reverse strand, blue for forward strand. The bridged coverage for the 
region is illustrated by the shaded area. The green dotted line on the y-axis indicates the 
bridged coverage averaged across the entire genome (normalized to estimate 2N and 1N). 
Inspection of the bridged coverage will reveal possible copy number changes near the 
breakpoint. Genes within the region are displayed, indicating exon location and strand 
direction. Thus, the junction plot illustrates: 1) the genomic position and strand of each 
read supporting the junction: 2) local and genome-wide bridged coverage; and 3) nearby, 
possibly affected, genes. B) Region plots are drawn only for intra-chromosomal 
rearrangements, are similar to junction plots, except breakpoint A, breakpoint B, and the 
genomic segment in-between, are all shown in one panel. 
Chapter 3: Sensitivity and junction detection performance of SVAtoolsJD compared to 
traditional cytogenetic techniques 
3A: SV Detection Method Comparisons 
SVAtools’ junction detection sensitivity was evaluated from a test set of breakpoints, collected 
from the cytogenetic results of the 29 patients. The test set included 285 breakpoints from 87 
rearrangements clinically reportable by at least one of the cytogenetic methods. Table 3A.1 is a 
heat map summarizing the detection of each rearrangement both quantitatively and qualitatively 
for each cytogenetic method and SVAtoolsJD: quantitatively by the number of breakpoints 
detected in each rearrangement, and qualitatively based on ability to reconstruct the 
rearrangement. For example, CMA can detect the breakpoints involved in a copy number loss 
and gain, but cannot demonstrate that these imbalances are secondary to an unbalanced 
translocation. Table 3A.2 is a heat map summarizing the number of breakpoints detected per 
sample for each cytogenetic method and SVAtoolsJD. The sensitivity of SVAtoolsJD compared to 
each cytogenetic method is shown in Table 3A.3 
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Table3A.1: Assessment of method performance for individual rearrangements. * 
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*Assessment of method performance for each rearrangement. A) Each row represents a 
unique rearrangement evaluated across multiple methodologies. The 29 samples 
contained 87 unique rearrangements total. Two heat maps are shown to reveal the 
quantitative and qualitative detection performance of each method: B) Quantitative 
assessment: Breakpoints Detected. Each cell shows the number of breakpoints detected 
by each of the four test methods and is color coded to indicate the level of breakpoint 
detection: green, orange and red, for all, partial and no breakpoints detected respectively. 
Gray cells indicate breakpoints not tested by FISH; 48% (137/285) of breakpoints in this 
study. C) Qualitative assessment: Rearrangement Detected. Each cell indicates if the 
method fully described and reconstructed the rearrangement. For example CMA detects all 
the breakpoints in an unbalanced translocation but does not reveal the structure of the 
rearrangement. 
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Table 3A.2: Assessment of method performance per sample * 
 
* Heat map of breakpoints detected per sample for each method. Each cell is color coded 
by percentage of breakpoints detected. Green = 100%, light green = 67-99%, yellow=34-
66%, orange = 1-33%, red = 0% 
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Table 3A.3: Sensitivity of MPseq with SVAtoolsJD, compared to each cytogenetic method. * 
 
karyotype FISH CMA 
 breakpoints 138 119 163 
 
 
 
   
MPseq with 
SVAtoolsJD 
breakpoints 
reported 120 109 137 
not reported 18 10 26 
Sensitivity all 
87% 92% 84% 
in >25% of cells 97% 100% 90% 
* based on detection of all breakpoints in each method and detection of breakpoints 
observed in greater than 25% of cells 
 
3A-1: Karyotype to MPseq with SVAtoolsJD comparison 
Karyotype analysis revealed 36 rearrangements, with a total of 138 predicted breakpoints (Table 
3A.3). Of the 38 rearrangements, only 7 were simple rearrangements with one junction each, 
such as deletions and unbalanced translocations. Of the 138 breakpoints, SVAtoolsJD reported 
120 breakpoints for 87% sensitivity. Of the 18 breakpoints not detected by SVAtoolsJD, 4 
breakpoints mapped to the centromere, and the remaining 14 were observed in tumors with a low 
clonal proportion: 6 in 15%, 8 in 25%. When only breakpoints with greater than 25% of clonal 
proportion are considered, the SVAtoolsJD sensitivity compared to karyotype is 97%. Of note, the 
6 breakpoints seen in 15% of cells were actually detected by SVAtoolsJD but were part of a 
complex t(15;17) translocation observed on multiple chromosome copies: 
46,XX,t(15;17)(q22;q21)[17]/46,XX,der(15)t(15;17)(q22;q21),ider(17)(q10)t(15;17)(q22;q21)[3] 
Karyotype identified the presence of the low level translocation in addition to the balanced 
translocation in 17/20 cells. SVAtoolsJD clustered all supporting fragments together to report only 
one balanced translocation. Despite not fully characterizing all rearrangements in the clone, the 
disease-defining rearrangement for the sample was detected by SVAtoolsJD. 
 
3A-2: FISH to MPseq with SVAtoolsJD comparison 
FISH analysis revealed 32 rearrangements, with a total of 119 predicted breakpoints (Table 
3A.3). SVAtoolsJD reported 106/119 breakpoints for 91% sensitivity. Of the 10 breakpoints not 
detected by SVAtoolsJD, 6 are the same breakpoints mention previously in the karyotype 
comparison (part of a complex translocation observed on multiple chromosome copies seen in a 
clonal proportion of 15%). The remaining 4 false negative breakpoints included 2 each from 
tumors with 6% and 25% clonal proportion. When only breakpoints found in 25% of cells or more 
are considered, the SVAtoolsJD sensitivity compared to FISH is 100%. 
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3A-3: CMA to MPseq with SVAtoolsJD comparison 
CMA analysis revealed 64 rearrangements, with a total of 163 predicted breakpoints (Table 
3A.3). SVAtoolsJD reported 137/163 breakpoints by junction detection for 84% sensitivity, 
increasing to 90% sensitivity (137/153) when only breakpoints found in 25% of cells or more are 
considered. Of the remaining 16 breakpoints not detected, 14 occurred at edges of a CNV 
detected by SVAtools’ CNV detection methods, including 4 centromeric breakpoints. Thus similar 
to CMA, for these 14 breakpoints SVAtools could detect the CNV but not the junction. Part of a 
nested deletion detected by CMA, 9p21.3p21.3(21772930_22215463)x1[0.4], but not SVAtoolsJD 
accounts for the remaining false negative breakpoint. SVAtoolsJD did detect a junction with 2 
supporting fragments but requires at least 3 fragments for reporting. FISH detected the adjacent 
deletion (CDKN2Ax1,D9Z1x2)[40/200] reported by CMA at 
9p22.1p21.3(19625174_21767405)x1[0.2], but did not test, thus confirm, this deletion reported by 
CMA. 
 
3B: Multi-method comparison: Karyotype, FISH, CMA, and MPseq with SVAtoolsJD 
Combining the full set of breakpoints for each cytogenetic method enables a comparison of each 
method’s ability to detect breakpoints. Because each of the three cytogenetic methods has 
advantages and limitations, this comparison better illustrates the detection performance of 
SVAtoolsJD (Table 3B). For the three cytogenetic methods, a combined total of 285 breakpoints 
were detected from 87 rearrangements. SVAtoolsJD reported 87% (249/285) of breakpoints.  
 
Table 3B: Multi-method comparison: karyotype, FISH, CMA and MPseq with SVAtoolsJD. *  
 
karyotype FISH CMA MPseq with SVAtoolsJD 
breakpoints     
reported 138 119 163 249 
not reported 151 29 / 166 122 36 
Total 285 148 / 285 285 285 
Detection 
performance 49% 80% / 42% 57% 87% 
*SVAtoolsJD achieved 87% detection performance, the highest of all methods, for the 
combined total of 285 breakpoints. 
 
Although FISH is known to be a very sensitive test, FISH was found to have the lowest detection 
performance 41% (119/285) (Table 3B) in the multi-method comparison. The low detection 
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performance reflects that FISH did not test 48% (137/285) of the breakpoints due to panel design 
or ordering practices. If the 137 breakpoints not tested are excluded from the total, FISH 
detection performance is 80% (119/148). FISH results did not always reveal the full nature of the 
rearrangement or report a CNV when the variant was outside the probe region. For example in 
sample EV88085, the FISH result (ABL1x3)(BCRx3),(ABL1 con BCRx1)[405/500], identifies more 
than 2 breaks but the investigator does not know where and does not know how many breaks. In 
comparison, both karyotype and SVAtoolsJD reported a four-way translocation, 
t(X;10;9;22)(q11;p13;q34;q11.2). FISH did detect the BCR-ABL1 fusion it was designed for, but 
not the ABL1 and MSN truncation, or the MSN->BCR fusion predicted by SVAtoolsJD by the other 
three junctions. Illustrating the other common limitation of FISH, in four samples from this study 
(including one example discussed below), FISH detected a heterozygous loss, but not the 
adjacent homozygous loss. 
 
Karyotype detected 48% (138/285) of all breakpoints in the multi-method comparison (Table 3B). 
Often karyotype was returned normal due to poor metaphase quality. Over half of all breakpoints 
not reported by karyotype were because the rearrangement was too small to detect. The 
remaining breakpoints not reported were due to misinterpretation or under-appreciation of 
complex rearrangements. For example, the karyotype for sample EV88059 karyotype reported a 
balanced rearrangement, t(5;6)(q13;q23), but by SVAtoolsJD this is more complex, 5q13 and 6q23 
are part of a 3-way translocation between chromosomes 5 and 6, with inversion and 2 losses 
(30Mb and 5 Mb) on chromosome 6. The losses were confirmed by CMA. There is a junction 
detected, but not reported by SVAtoolsJD, connecting the left edges of each of the two 
chromosome 6 losses. The junction was not reported because it had only 2 supporting fragments; 
at least 3 fragments are required for reporting. SVAtools CNV detection did however report the 
edges of the CNV, and similar to FISH, since the region of interest is known, interrogation of the 
data was possible which revealed the low-level junction. Knowledge of this junction allows for 
complete reconstruction of the rearrangement. Sample EV88101 also illustrates this karyotype 
limitation. The karyotype reported a deletion, del(11)(q21q23), and an add(19)(q13.1). FISH 
((KMT2Ax2)[200]) and CMA were normal, while SVAtools detected a balanced translocation, 
t(11;19)(q21;q13.11). This deletion was counted as a false positive for karyotype and a true 
negative for FISH, CMA, and SVAtoolsJD. 
 
CMA detected 57% (163/285) of all breakpoints in the multi-method comparison (Table 3B). 
Based on the rearrangement characterization by SVAtoolsJD, 63% (102/163) of the CMA 
breakpoints were due to a rearrangement other than a simple deletion or tandem duplication. 
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Thus, while CMA could report the CNV, the nature of the rearrangement was not reported. Of the 
122 breakpoints not reported by CMA, 92% (112/122) were due to undetected balanced 
rearrangements such as inversions and balanced translocation. Of the remaining 10 breakpoints 
not detected by CMA, 6 breakpoints were from a deletion or unbalanced translocation reported by 
FISH. The remaining 4 breakpoints were complex rearrangements detected by karyotype. 
Chapter 4: Additional advantages of MPseq and SVAtoolsJD over traditional cytogenetic 
techniques 
4A: Resolving Ambiguous, Cryptic and Complex Rearrangements with SVAtoolsJD 
In addition to the higher detection performance of SVAtoolsJD compared to standard cytogenetic 
methods, SVAtoolsJD can more completely characterize the rearranged genome by: 1) resolving 
the genomic configuration of complex rearrangements, and 2) reporting the breakpoints at a 
much higher resolution. To illustrate these points, five samples are described below. For each 
sample, the relevant cytogenetic test results for each method, the SVAtoolsJD results and the 
inferred molecular karyotype are listed. All positions are listed in GRCh38 coordinates. The RF, 
FR, FF, and RR columns refer to the number of fragments mapping to the corresponding strand 
orientation where R is reverse and F is forward, for position A and position B respectively. 
 
In sample EV88100, SVAtoolsJD reports three non-complex junctions that required both karyotype 
and CMA to detect (Figure 4A.1), the inv(3), del(5), and the unbalanced translocation, 
der(17)t(11;17). SVAtoolsJD clarified the karyotype findings, demonstrating the add(17) as an 
unbalanced derivative and reported a possible VAMP2->BCO2 fusion. While FISH test 
demonstrated the inv(3), a standard FISH panel for MDS does not test for t(11;17) 
rearrangements. CMA demonstrated the del(5) and the deletion/duplication associated with the 
7;11 translocation, however the derivative chromosome 17 could only be inferred, and the 
balanced inversion 3 was missed. Individually karyotype, FISH, and CMA provide a piece of the 
puzzle, but SVAtoolsJD provides a comprehensive understanding of the SVs in the neoplasm. 
Junction plots for these three rearrangements are in Figure 4A.2 
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A 
Sample EV88100 RFR: acute leukemia, MDS 
Karyotype 46,XX,inv(3)(q21q26.2),del(5)(q13q33),add(17)(p13)[20] 
FISH (RPN1x3),(EVI1x3),(RPN1 con EVI1x2)[454/500]/ (D5S630x2,EGR1x1)[198/200]/(MLLx3)[185/200] 
CMA 
Locus 
Start 
Locus 
End 
Position 
Min 
Position 
Max Size Type 
11q23.1 11q25 112,186,582 135,068,576 22,881,994 Gain 
17p13.3 17p13.1 150,732 8,158,478 8,007,746 Loss 
5q14.2 5q33.2 82,326,551 153,894,589 71,568,038 Loss 
MPseq with 
SVAtoolsJD 
Locus 
A 
Locus 
B Position A Position B Size RF FR FF RR 
11q23.1 17p13.1 112,187,010 8,158,594 NA 0 0 12 1 
3q21.3 3q26.2 128,546,376 168,886,142 40,339,766 0 17 10 2 
5q14.2 5q33.2 82,326,442 153,901,421 71,574,979 26 1 0 0 
Inferred Mol. 
Karyotype   
seq inv(3)(q21q26.2),del(5)(q14.2q33.2),der(17)t(11;17)(q23.1;p13.1) 
 
B 
 
Figure4A.1: EV88100 a sample with three non-complex junctions. 
A) Results of each SV detection method B) genome plot showing the copy number and 
junctions for each of the three rearrangements: del(5), inv(3) and t(11;17). 
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Figure 4A.2: EV88100 junction plots  
A) del(5), B) inv(3) and C) t(11;17) 
 
In sample EV88059, SVAtoolsJD reports two junctions on chromosome 13 (Figure 4A.3), resulting 
in a nested deletion: two overlapping deletions, 2,194 kb and 960 kb, with a 133kb homozygous 
loss including TRIM13, KCNRG, and the 3’ end of DLEU2. This nested deletion illustrates a major 
limitation of FISH related to detection of deletion/duplication below the resolution of the probe. 
FISH reported one heterozygous loss, but missed the focal homozygous deletion. Karyotype was 
normal for chromosome 13. CMA revealed the homozygous loss and the two adjacent 
heterozygous deletions; however, the structural nature of the rearrangement could not be 
characterized. The junction plots (Figure 4A.4) used to reconstruct chromosome 13 (Figure 4A.5) 
are shown below. 
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A 
Sample EV88059 RFR: CLL 
Karyotype 46,XY,t(5;6)(q13;q23)[10]/47,XY,+12[2]/46,XY[8] (Normal 13) 
FISH (D13S319x1),13q34(LAMP1x2)[112/200] 
CMA 
Locus 
Start 
Locus 
End Position Min 
Position 
Max Size Type 
13q14.2 13q14.2 47,898,938 49,957,631 2,058,694 loss 
13q14.2 13q14.2 49,971,104 50,097,568 126,464 loss 
13q14.2 13q14.3 50,108,920 50,922,184 813,264 loss 
MPseq with 
SVAtoolsJD 
Locus A Locus B Position A Position B Size RF FR FF RR 
13q14.2 13q14.2 47,897,178 50,091,564 2,194,386 13 0 0 0 
13q14.2 13q14.3 49,958,440 50,918,770 960,330 13 0 0 0 
Inferred Mol. 
Karyotype 
seq del(13)(q14.2q14.2, del(13)(q14.2q14.3) 
 
B 
 
Figure 4A:3 EV88059, a sample with a nested deletion  
A) Results of each SV detection method B) genome plot view of chromosome 13 showing 
the copy number and junctions C) region plot of chromosome 13 between 46.8-52 MB. The 
red dot-gray line-blue dot clusters represent the two deletion junctions reported. 
 
  
C 
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Figure 4A.4: EV88059 junction plots 
A) del(13)(q14.2q14.2), B) del(13)(q14.2q14.2) 
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Figure 4A.5: EV88059 chromosome 13 reconstruction 
A) chromosome 13 segmented by the CNV and junctions, as shown on the genome plot 
view B) both copies of the reconstructed chromosome 13, in both 49.958kb-50,091kb (the 
orange segment) is deleted, while in the top copy 50,091-50,919kb is deleted (the purple 
segment) and in the bottom copy 47,897-49,958kb (the blue segment) is deleted. 
 
In sample EV88081, SVAtoolsJD clearly illustrates the presence of a 4-way rearrangement 
involving chromosomes 1, 4, and 11 (Figure 4A.6), which is missed by karyotype and CMA, and 
only implied by an atypical FISH result. The karyotype was reported normal, even though these 
would by cytogenetically visible rearrangements, due to the notorious difficulty in obtaining 
suitable metaphase preparations from B-ALL samples. CMA missed the 4-way rearrangement 
because it cannot detect balanced translocations. The FISH probes AFF1/KMT2A(MML) suggest 
a 3-way break, but reveal nothing about involvement of chromosome 1 in this rearrangement. 
Reconstructing the genomic rearrangement from the four junctions results in three altered 
chromosomes. The inv(1) is not a standard 2-junction inversion because the reunion of one 
inversion break occurs by the unbalanced translocation between chromosome 1 and 11. The 
inferred molecular karyotype is also written in long form for der(1) to fully describe the location of 
the inv(1) with respect to the der(1)t(1;11). The junction plots (Figure 4A.7) and the reconstructed 
chromosomes: der(1), der(4), and der(11) are shown below (Figure 4A.8).  
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A 
Sample EV88081 RFR: non-Hodgkin’s, B-ALL 
Karyotype 46,XX[20] 
FISH 
 (AFF1x3),(KMT2Ax3),(AFF1 con KMT2Ax1)[167/500]   
CMA 
Locus 
Start 
Locus 
End 
Position 
Min  
Position 
Max  Size Type 
1         normal 
4         normal 
11         normal 
MPseq 
with 
SVAtoolsJD 
Locus A Locus B Position A Position B Size RF FR FF RR 
1p13.2 4q21.3 111,521,195 87,070,888  NA  0 0 0 11 
1q23.2 11q23.3 159,782,738 118,486,390  NA  18 1 0 0 
4q21.3 11q23.3 87,074,163 118,483,487  NA  0 20 0 0 
1p13.2 1q23.2 111,523,206 159,785,532 48,262,326 0 0 9 0 
Inferred 
Mol. 
Karyotype  
seq der(4)t(1;4)(p13.2;q21.3),der(11)t(4;11)(q21.3:q23.3),der(1)t(1;11)(q23.2;q23.3), 
inv(1)(p13.2q23.2)  
der(1) in 
long form seq der(1)(1qter->1q23.2::1p13.2->1q23.2::11q23.3->11qter 
 
B
 
Figure 4A.6: EV88081 a sample with a complex four-way rearrangement. 
A) Results of each SV detection method B) genome plot showing the copy number and 
junctions for the sample, including the four way rearrangement involving chromosomes 1, 
4, and 11.  
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Figure 4A.7: EV88081 junction plots 
A) der(4)t(1;4), B) der(11)t(4;11) C) der(1)t(1;11) D) der(1)inv(1) 
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Figure 4A.8: EV88081 chromosome 1, 4, and 11 reconstruction. 
A) chromosome 1, 4, and 11 each segmented by the CNV and junctions, as shown on the 
genome plot view B) the reconstructed derivative chromosomes for der(1), der(4) and 
der(11). The centromere location is indicated by the gray hourglass shape. 
 
In sample EV88102, the karyotype is normal while CMA reports two apparently independent 
losses. SVAtoolsJD reports four junctions to indicate a complex rearrangement (Figure 4A.9). On 
chromosome 6, SVAtoolsJD reports 2 copy number losses and 4 junctions, indicating the segment 
in-between the two deletions is inverted. CMA is the only cytogenetic method that revealed any 
SV on chromosome 6; however, the structural nature of the rearrangement could not be 
characterized by CMA. The region plot provides a zoomed in view of the genomic region and 
illustrates the strand orientation for the breakpoints in all four junctions. Similar to sample 
EV88081, the inversions on chromosome 6 are not typical two-junction inversions. The reunion of 
one inversion break occurs with a breakpoint from the other inv(6). The long form of the inferred 
molecular karyotype is provided to show that two small, 17kb and 7kb, regions, from within the 
first deleted area are maintained but translocated within chromosome 6. The junction plots 
(Figure 4A.10) and the reconstructed chromosome (Figure 4A.11) are shown below. 
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A 
Sample EV88102 RFR: B-ALL 
Karyotype 46,XX[20] 
FISH 
 No test on chr6 (B-ALL Panel) 
CMA 
Locus 
Start 
Locus 
End 
Position 
Min 
Position 
Max Size Type 
6q14.1 6q22.1 79,537,678 115,628,290 36,090,610 Loss 
6q24.2 6q25.1 144,025,781 150,147,794 6,122,013 Loss 
MPseq 
with 
SVAtoolsJD 
Locus A Locus B Position A Position B Size RF FR FF RR 
6q14.1 6q14.3 78,834,079 84,715,197 5,881,118 0 0 1 15 
6q14.1 6q24.2 78,811,728 143,698,666 64,886,938 0 0 0 21 
6q14.1 6q22.1 78,816,584 115,311,472 36,494,888 0 0 15 1 
6q14.3 6q25.1 84,708,247 149,831,163 65,122,916 0 0 14 0 
Inferred 
Mol. 
Karyotype   
seq der(6)del(6)(q14.1q22.1);inv(6)(q22.1q24.2);del(6)(q24.2q25.1)   
der(6) in 
long form seq der(6)(6pter6q14.1::6q24.26q22.1::6q14.16q14.1::6q14.36q14.3::6q25.16qter 
 
B
 
Figure 4A:9 EV88102, a sample with a complex inversion deletion rearrangement 
A) Results of each SV detection method B) genome plot view of chromosome 6 showing 
the copy number and junctions C) region plot of chromosome 6 between 76-160 MB. The 
dot-line-dot clusters represent the supporting fragments for each of the four junctions 
reported. 
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Figure 4A.10: EV88102 junction plots 
A) der(6)inv(6;6)(q14.1q24.2), B) der(6)inv(6;6)(q14.1q22.1) C) der(6)inv(6;6)(q14.3;25.1)  
D) der(6)inv(6;6)(q14.1q14.3) 
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Figure 4A.11: EV88102 chromosome 6 reconstruction 
A) Chromosome 6 p arm segmented by the CNV and junctions, as shown on the genome 
plot view B) the reconstructed derivative chromosome 6.  
 
In the last example EV88099, FISH reveals there is a gain or disruption on chromosome 10 and 
karyotype reports a balanced translocation but not involving the same location as FISH. CMA was 
normal. SVAtoolsJD reports a balanced translocation, an inversion, and predicts a clinically 
relevant fusion gene (Figure 4A.12). The FISH result (MLLT10x3)[355/500] can be interpreted as 
a gain or disruption of the region, but requires additional testing to determine which scenario and 
any possible partners. The karyotype, t(X;10)(q24;p13), reports a translocation, but not at 
MLLT10. SVAtoolsJD reported two rearrangements: t(X;10)(p11.4;p12.31) and 
inv(X)(p11.22;q22.3). The balanced translocation predicts the fusion DDX3X->MMLT10. Neither 
FISH, karyotype, nor CMA reported this junction or predicted this fusion. FISH was not specific 
enough. The inversion likely complicated the ability for karyotype to identify the breakpoints for 
the translocation. CMA cannot detect balanced rearrangements. The junction plots (Figure 4A.13) 
and the reconstructed chromosome (Figure 4A.14) are shown below. 
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A 
Sample EV88099 RFR: T-ALL 
Karyotype 48,X,t(X;10)(q24;p13),+1,+4[6]/46,XX[14] 
FISH (STIL,TAL1)x3[125/200]/(MLLT10x3)[355/500] 
CMA 
Locus 
Start 
Locus 
End 
Position 
Min 
Position 
Max Size Type 
10 
    
normal 
X 
    
normal 
MPseq 
with 
SVAtoolsJD 
Locus A Locus B Position A Position B Size RF FR FF RR 
10p12.31 Xp11.4 21,573,217 41,343,223 NA 9 15 0 0 
Xp11.22 Xq22.3 52,359,209 105,395,051 53,035,842 0 1 5 5 
Inferred 
Mol. 
Karyotype  
seq  48,X,t(X;10)(p11.4;p12.31),+1,+4,inv(X)(p11.22;q22.3) 
 
B
 
Figure 4A.12: EV88099 a sample with a balanced translocation. 
A) Results of each SV detection method B) genome plot showing the copy number and 
junctions for the sample, including the balanced translocation t(X;10) and the inversion 
inv(X). 
  
 47 
A 
  
 
B 
  
Figure 4A.13: EV88099 junction plots 
A) t(X;10) B) inv(X) 
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Figure 4A.14: EV88099 chromosome 10 and X reconstructions 
A) chromosome 10 and X each segmented by the CNV and junctions, as shown on the 
genome plot view B) the reconstructed derivative chromosomes for der(10), and der(X). 
The centromere location is indicated by the gray hourglass shape. 
 
4B: Resolution of breakpoints 
Fragments with split reads were detected in three of the 18 junctions from the five samples 
described above. The automated SVAtools pipeline includes split reads for junction detection, but 
not for reporting the exact breakpoint position. However, the split reads can be analyzed by 
manual methods to pinpoint the exact molecular breakpoint. Comparison of the actual breakpoint 
provided by split reads demonstrates that the estimated breakpoint positions reported were within 
24-151 bps (Table 4B).  
 
Table 4B: MPseq with SVAtoolsJD breakpoint resolution.* 
   
As reported by split reads As reported by pipeline difference 
Sample Chr A Chr B Position A Position B Position A Position B Pos. A Pos. B 
EV88100 3q21.3 3q26.2 128,543,682 168,886,550 128,543,833 168,886,484 151 66 
EV88100 5q14.2 5q33.2 82,327,433 153,899,622 82,327,333 153,899,576 100 46 
EV88102 6q14.1 6q22.1 78,815,300 115,310,195 78,815,276 115,310,166 24 29 
*Split reads have 1bp resolution revealing the molecular breakpoint. Listed are three 
junctions which each contained a split read. The difference in the breakpoint position 
reported by the pipeline versus the breakpoint position as determined by the split reads, 
ranges between 24-151 bps 
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4C: Fusion genes and truncated genes 
SVAtoolsJD can predict fusion and truncated genes based on the strand orientation of the genes 
at the junction and strand orientation of fragments crossing the junction. The high breakpoint 
resolution of MPseq also allows SVAtoolsJD to pinpoint which intron or exon is bisected. From the 
18 junctions in the five examples described earlier, seven fusion genes and six truncated genes 
are predicted. (Table 4C) 
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Table 4C: SVAtoolsJD gene prediction. *  
Sample Locus A Locus B Position A Position B Size Gene prediction RF FR FF RR 
EV88100 11q23.1 17p13.1 112,185,770 8,156,561 NA VAMP2 -> BCO2 0 0 12 1 
EV88059 13q14.2 13q14.2 47,897,178 50,091,564 2,194,386 DLEU1 truncation DLEU2 truncation  13 0 0 0 
EV88059 13q14.2 13q14.3 49,958,440 50,918,770 960,330 RNASEH2B truncation  13 0 0 0 
EV88081 1p13.2 4q21.3 111,521,879 87,072,561 NA AFF1 -> TMIGD3 0 0 0 11 
EV88081 1q23.2 11q23.3 159,783,606 118,484,864 NA DUSP23 -> KMT2A 18 1 0 0 
EV88081 4q21.3 11q23.3 87,072,957 118,484,261 NA KMT2A -> AFF1 0 20 0 0 
EV88081 1p13.2 1q23.2 111,523,206 159,785,532 48,262,326 TMIGD3 truncation 0 0 9 0 
EV88102 6q14.1 6q24.2 78,812,237 143,700,068 64,887,831 PHACTR2 truncation 0 0 0 21 
EV88102 6q14.3 6q25.1 84,708,036 149,828,844 65,120,808 LRP11->TBX18-AS1 0 0 14 0 
EV88099 10p12.31 Xp11.4 21,573,217 41,343,223 NA DDX3X->MLLT10 MLLT10-> DDX3X  9 15 0 0 
EV88099 Xp11.22 Xq22.3 52,359,209 105,395,051 53,035,842 IL1RAPL2 truncation 0 1 5 5 
*SVAtoolsJD will detect and report possible gene fusions or truncations based on the rearrangement configuration. Gene fusions or 
truncations were detected in 13 of 18 junctions from the 5 examples. The “Gene prediction” column lists the gene(s) involved and the 
orientation of the fusion. All positions are listed in GRCh38 coordinates. The RF, FR, FF, and RR columns refer to the number of 
fragments mapping to the corresponding strand orientation where R is reverse and F is forward, for position A and position B 
respectively. 
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Chapter 5: Discussion and Summary 
Fragments produced by MPseq include both concordant (95%) and discordant (5%) fragments. 
SVAtoolsJD detects junctions by clustering the discordant fragments with read-pair and split read 
approaches, and detects CNVs from the concordant fragments with the read depth approach. 
Few SV callers include all three approaches: read-pair, split read, and read depth (Tattini, 
D'Aurizio, and Magi 2015; Lin et al. 2015). Because SVAtools detects both junctions and CNVs, 
SVAtools can integrate the results of both to further refine SV calls, improve sensitivity and 
breakpoint resolution. While the limits of detection are still being validated for MPseq, the current 
BMD-SV pipeline methods used in this study indicate detection of breakpoints observed in more 
than 25% of cells to be highly sensitive. With these criteria, SVAtoolsJD detected 97%, 100% and 
90% of the breakpoints detected by karyotype, FISH, and CMA respectively. If SVAtools’ CNV 
detection without a supporting junction is included, 93% (265/285) of breakpoints are reported by 
SVAtools. Additionally, when only breakpoints detected in at least 25% of cells are considered, 
SVAtools detected 99% (263/266) of the breakpoints.  
 
While karyotype and FISH can both report balanced and unbalanced rearrangements, there are 
drawbacks to each. FISH is limited to the probed area. FISH is not whole genome and the 
investigator must know which genomic region to interrogate to perform a successful FISH test. 
Karyotype requires dividing cells and the standard of testing only 20 cells may not be statistically 
representative of the sample. Often karyotype is returned normal due to more metaphase quality 
and resolution is limited to the cytoband level. CMA is capable of providing higher breakpoint 
resolution than either karyotype or FISH; however CMA cannot detect balanced rearrangements 
or provide insight as to genomic structure when a copy number change is detected. Clinically, a 
gain or loss may not be significant, but a rearrangement involving these CNVs would be missed 
and may be significant. Identifying disrupted genes and regulatory elements is important for 
prognosis and treatment. Dosage effects of genes within gains and losses can be inferred by 
CMA, but the impact on a gene at the junction of a gain or losses cannot. 
  
Junction detection, regardless of the algorithm employed, has some inherent limitations. Junction 
detection is limited to non-terminal rearrangements because terminal rearrangements only have 
one break and no junction, for example no junction will be reported if a gain at a terminal edge is 
a tandem duplication. However, terminal CNVs, including whole arm and whole chromosome 
CNVs can be detected by SVAtools’ CNV detection methods. Junction detection will also fail to 
detect junctions in regions excluded from the reference genome including the heterochromatic 
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regions of chromosome 1, 9 and 16. Similar to CMA, losses and gains of the p-arm of the 
acrocentric chromosomes cannot be detected, while not clinically significant, rearrangements 
involving these locations would also be missed and may be significant. Junction detection also 
struggles in genomic regions with high sequence similarity. Fortunately, the long insert size of 
mate-pair fragments facilitates mapping of concordant reads in repeat areas, an advantage of 
MPseq over traditional paired-end sequencing. Thus read depth coverage often catches these 
missed junctions, however junctions occurring at the centromere are often filtered out due to high 
homology scores. Finally, junction detection can report low-level rearrangements, but like most 
algorithms, not without reporting false positives. For junctions detected by cytogenetic methods at 
very low levels, changes to the BMD-SV pipeline to improve coverage would facilitate increased 
junction detection sensitivity. Such changes could include sequencing at a higher depth, limiting 
normal cell contamination in the library preparation, and increasing the length of the mate-pair 
fragment insert size. Single nucleotide variant (SNV) detection is not possible with the current 
BMD-SV pipeline methods. Referring back to the example from section 2C, a depth of coverage 
suitable for detecting junctions, 93.75x bridged coverage, results in a depth of coverage not 
suitable for detecting single nucleotide variants (SNVs), 6.25x base coverage. 
 
In clinical practice often two or more cytogenetic assays are performed to detect clinically relevant 
rearrangements and copy number changes. One test will be ordered and then reflexed to 
another, adding time and cost to the analysis. While karyotype detects a number of clinically-
relevant rearrangements, CMA or FISH are needed to detect submicroscopic imbalances. For the 
CMA first approach, the pattern of gain and loss detected is highly suggestive and the structural 
rearrangement can be inferred (sample EV88100) but in complex cases reflexing to FISH or 
karyotype is often required. Even after performing karyotype, FISH and CMA, the rearrangements 
may not be full described (samples EV88059, EV88081, EV88102, EV88099). In each of the 
examples described, SVAtoolsJD fully characterized each rearrangement and reported disrupted 
and/or fusion genes. In addition, the breakpoint resolution for MPseq with SVAtoolsJD is half the 
fragment size, but SVAtoolsJD typically reports the breakpoint to less than a couple hundred 
bases and can detect the exact breakpoint manually using split reads. This representative set of 
clinical cases demonstrates the potential advantage of performing a single MPseq test with 
SVAtoolsJD over running multiple cytogenetic tests and eliminating the need for extensive reflex 
FISH. Future work will include full validation of the clinical performance; both sensitivity and 
specificity, of MPseq with SVAtools to more clearly define the clinical readiness for this assay to 
replace current gold standard cytogenetic techniques. 
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